Long-term results of oxybutynin treatment for palmar hyperhidrosis

Wolosker, Nelson; Teivelis, Marcelo Passos; Krutman, Mariana; Paula, Rafael P. de; Campos, José Ribas Milanez de; Kauffman, Paulo; Puech-Leão, Pedro

doi:10.1007/s10286-014-0264-8

Cited by 39 publications

(44 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dry mouth was the most commonly recorded adverse event and affected patients in the long term . All of the studies documented evidence of dry mouth, and results were consistent between different drug therapies and patient cohorts.…”

Section: Resultsmentioning

confidence: 68%

Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review

Cruddas

Baker

2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

Primary hyperhidrosis is a condition characterized by excessive sweating. Patients are treated off-license with oral anticholinergic medications and report adverse events associated with systemic anticholinergic interactions. This review assesses clinical evidence of efficacy, impact on quality of life and adverse events associated with oral anticholinergic therapy for primary hyperhidrosis. PRISMA guidelines were implemented to complete a systematic review (PROSPERO:CRD42016036326). MEDLINE, EMBASE and PubMed were searched from 1946 to 2015. Inclusion criteria included observational and experimental studies, anticholinergic medication use in primary hyperhidrosis, oral therapy and clear diagnostic and outcome measures. Twenty-three articles relevant to the inclusion criteria were analysed. Oxybutynin therapy improved symptoms in an average of 76.2% (range 60-97%) patients and improved QOL in 75.6% (range 57.6-100%) of patients. Methantheline bromide therapy was associated with a 41% reduction in axillary sweating, 16.4% reduction in palmar sweating, 25% decrease in HDSS score and 40.9% increase in DLQI score. Outcome measures of glycopyrrolate therapy were too variable to collate. Dry mouth was reported in 73.4% (range 43.3-100%) of participants taking oxybutynin 10 mg/day, 38.6% (range 27.8-63.2%) of patients taking glycopyrrolate and 68.8% of patients taking methantheline bromide. Nine studies reported that patients stopped therapy due to adverse events. In eight of these studies, a mean of 10.9% of total participants ceased treatment due to dry mouth. Evidence of oral anticholinergic therapy for hyperhidrosis is limited. However, its use is associated with improvement in quality of life and clinical symptoms but at the cost of considerable adverse events.

show abstract

Section: Resultsmentioning

confidence: 68%

Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review

Cruddas

Baker

2017

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4] One such drug is oral oxybutynin, which is the most commonly used and which has been the most extensively studied, 1-4 although its US Food and Drug Administration-approved indication is the treatment of bladder instability associated with incontinence in patients with neurogenic bladder. [1][2][3][4] One such drug is oral oxybutynin, which is the most commonly used and which has been the most extensively studied, 1-4 although its US Food and Drug Administration-approved indication is the treatment of bladder instability associated with incontinence in patients with neurogenic bladder.…”

Section: Introductionmentioning

confidence: 99%

Initial study of transdermal oxybutynin for treating hyperhidrosis

Millán‐Cayetano

Boz

Toledo-Pastrana

et al. 2017

The Journal of Dermatology

View full text Add to dashboard Cite

Oral oxybutynin for treating hyperhidrosis is effective and safe. Its side-effects are mild but frequent so we consider whether transdermal oxybutynin (considered to have a better side-effect profile) could be an alternative for treating hyperhidrosis. During 2015, a prospective study was conducted. Epidemiological variables, effectiveness (using the Hyperhidrosis Disease Severity Scale) and tolerance to transdermal oxybutynin were compiled concerning two different groups (patients previously treated or untreated with oral oxybutynin), at baseline, and at 3 and 12 months. Seven previously treated and six previously untreated patients were included. Five patients in the first group discontinued the treatment within 3 months. Of the two remaining patients, one reported ineffectiveness and the other obtained an excellent response but discontinued due to local irritation. Among the untreated patients, two showed no response and four experienced improvement (three with "partial response" and one with "excellent response"). All patients discontinued treatment within 12 months. No major adverse effects were observed. The absence of active metabolites after transdermal oxybutynin could result in less effectiveness than oral oxybutynin, although it is usually well tolerated. In conclusion, transdermal oxybutynin could have low effectiveness for the treatment of hyperhidrosis in patients following intolerance to oral oxybutynin but could provide good results in patients who have never tried systemic drugs.

show abstract

“…Of the 246 patients with over six months of follow-up, 90.2% presented improvement. 49 In the plantar hyperhidrosis, out of 39 patients with follow-up longer than six months, all the women showed improvement in 84,7% of the cases (Chart 1). 50 …”

Section: Resultsmentioning

confidence: 95%

Oxybutynin as an alternative treatment for hyperhidrosis

Delort

Marchi

Corrêa

2017

An. Bras. Dermatol.

View full text Add to dashboard Cite

Hyperhidrosis is the excessive production of sweating, which can be primary and focal or secondary to various pathologies. The exact cause of primary focal hyperhidrosis is still unknown, although a genetic basis is recognized, and its prevalence varies from 1% to 2.8%. The most affected sites are the armpits, palms, soles and face. It causes much discomfort, affects the quality of life, and is estimated to be undervalued by health professionals. Many treatment options are proposed, both clinical and surgical. The aim of this review is to focus on the treatment of hyperhidrosis with oxybutynin, an anticholinergic drug originally used to control overactive bladder.

show abstract

Long-term results of oxybutynin treatment for palmar hyperhidrosis

Cited by 39 publications

References 26 publications

Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review

Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review

Initial study of transdermal oxybutynin for treating hyperhidrosis

Oxybutynin as an alternative treatment for hyperhidrosis

Contact Info

Product

Resources

About